BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4170552)

  • 1. [Sequential treatment. Experimental and clinical study].
    Di Paola G; Mendizábal A; Usubiaga I; Ortega F
    Rev Argent Endocrinol Metab; 1966 Sep; 12(3):158-72. PubMed ID: 4170552
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparative cytological and histological studies following the use of an ovulation inhibiting estrogen-gestagen combination (Ovositon)].
    Krause W; Böhm W; Müller W
    Gynaecologia; 1968; 166(5):432-45. PubMed ID: 4179218
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advantage of the use of an estroprogestational drug: 3 mg of chlormadinone acetate + 100 mcg of mestranol in endocrine gynecology].
    Bernard I
    Bord Med; 1970; 3(7):1954-60. PubMed ID: 4195405
    [No Abstract]   [Full Text] [Related]  

  • 4. Our experience with sequential estrogen-progestin treatments to inhibit ovulation.
    Cittadini E; Quartararo P; Romano F
    Int J Fertil; 1969; 14(2):180-7. PubMed ID: 4181574
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experiences with a gestagen-estrogen preparation (AK 103=Aconcen)].
    Kalchauer B
    Ther Ggw; 1966 Jul; 105(7):938-9. PubMed ID: 4162578
    [No Abstract]   [Full Text] [Related]  

  • 6. [Biphasic therapy using Sequenz-Ovosiston for hormonal contraception].
    Ebeling K; Kühndel K; Rothe K; Canzler E
    Z Arztl Fortbild (Jena); 1971 Dec; 65(24):1275-8. PubMed ID: 4111418
    [No Abstract]   [Full Text] [Related]  

  • 7. [Menstruation disorders due to Ovosiston medication].
    Kühndel K; Ebeling K; Rothe K
    Dtsch Gesundheitsw; 1971 Jan; 26(3):109-13. PubMed ID: 4106361
    [No Abstract]   [Full Text] [Related]  

  • 8. [Studies on the hormonal activity and progestagenic properties of Ovosiston preparation].
    Krzywdziński K; Jedrzejewski M; Teter J
    Ginekol Pol; 1969 Jan; 40(1):41-52. PubMed ID: 4181038
    [No Abstract]   [Full Text] [Related]  

  • 9. [Normal sequential treatment. experiences with an 11:10 variant of the sequential method for contraception and for medical indications].
    Schmidt H; Langner A; Kaiser R
    Munch Med Wochenschr; 1970 Oct; 112(42):1903-13. PubMed ID: 4097638
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical experience with the preparation Ovosiston with special reference to the cervix factor and vaginal cytology].
    Müller R; Kempf HJ; Eckert L
    Zentralbl Gynakol; 1968 Nov; 90(46):1545-55. PubMed ID: 4179333
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experiences with different doses of Ovosiston preparations within the scope of marital and sexual counseling. Individual therapy with oral contraceptives].
    Ebeling K; Kühndel K; Rothe K
    Dtsch Gesundheitsw; 1971 Jan; 26(1):31-4. PubMed ID: 4106517
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sequential therapy].
    Annee Endocrinol; 1967; 19():97-102. PubMed ID: 4173491
    [No Abstract]   [Full Text] [Related]  

  • 13. [Indications for the treatment with sequence preparations].
    Breckwoldt M; Bettendorf G
    Zentralbl Gynakol; 1969 Aug; 91(35):1147-50. PubMed ID: 4189508
    [No Abstract]   [Full Text] [Related]  

  • 14. [Femigen forte and mite preparations in contraception and gynecologival disorders].
    Sternadel Z; Pietrusiewicz W; Wasilewska B
    Ginekol Pol; 1970 Nov; 41(11):1227-36. PubMed ID: 4098877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined estrogen-progestagen-therapy in menstruation anomalies].
    Akasu F
    Arch Gynakol; 1971 Jun; 211(1):191-3. PubMed ID: 4103779
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sequential therapy in menstruation disorders].
    Gaudefroy M; Lefebvre F
    J Sci Med Lille; 1968 Oct; 86(10):581-606. PubMed ID: 4097276
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of menopause disorders by the sequential method].
    Gaudefroy M
    J Sci Med Lille; 1970 Dec; 88(12):637-49. PubMed ID: 4100661
    [No Abstract]   [Full Text] [Related]  

  • 18. [Use of an oral contraceptive Femigen-Polfa by epileptic women].
    Rościszewska D
    Neurol Neurochir Pol; 1973; 7(5):715-7. PubMed ID: 4128492
    [No Abstract]   [Full Text] [Related]  

  • 19. Behçet's disease. Alleviation of buccal and genital ulceration by an oral contraceptive agent.
    Hewitt AB
    Br J Vener Dis; 1971 Feb; 47(1):52-3. PubMed ID: 4101407
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of a new sequential contraceptive agent.
    Parkinson RW; McQuarrie HG; Ellsworth HS; Stone RA
    Obstet Gynecol; 1966 Aug; 28(2):239-46. PubMed ID: 4161460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.